Under siege : portraits of civilian life in France during World War I / / edited by Robert J. Young

• Record Nr.: UNINA9910827649103321
• Pubbl/distr/stampa: New York : , : Berghahn Books, , 2000
• ISBN: 1-57181-132-X; 1-57181-133-8; 1-78238-829-X
• Descrizione fisica: 1 online resource (216 p.)
• Disciplina: 940.53/44
• Soggetti: World War, 1914-1918 - France - Press coverage; France History German occupation, 1914-1918 Press coverage; France Social life and customs 20th century Press coverage
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references (pages 168-173) and indexes.
• Nota di contenuto: Under Siege; CONTENTS; ACKNOWLEDGEMENTS; INTRODUCTION; Chapter 1. 1914; Chapter 2. 1915; Chapter 3. 1916; Chapter 4. 1917; Chapter 5. 1918; EPILOGUE; SUGGESTIONS FOR FURTHER READING; APPENDIX; INDEX
• Sommario/riassunto: Studies on the First World War are plentiful but most tend to focus on the combatants. This volume offers a new and highly original perspective that shows the reader the civilian side of this protracted and destructive war through a succession of "snapshots": 130 excerpts from leading American and Canadian newspapers provide a collective portrait of life behind the battle lines, what is often called the "second" front. Written principally by Paris-based journalists, and intended for popular reading audiences, these articles depict ordinary people in a way that still touches the reader of today. They record eye-witness testimony of Paris under aerial bombardment, the gutted cathedrals at Reims and Arras, the cemeteries around Compiègne, the subterranean living quarters at Cambrai, and the heart-breaking orphanages at Chambly. Introduced and concluded by the editor, the volume also offers biographical notes on some of the leadingjournalist contributors, maps to familiarize readers with the geography of northern France, and ; detailed subject and geographical indices. The volume ends with a select bibliography of works on the subject of French civilian life during the Great War.

Frontiers in clinical drug research - CNS and neurological disorders . Volume 4 / / edited by Atta-ur-Rahman

• Record Nr.: UNINA9910808718803321
• Pubbl/distr/stampa: Sharjah, United Arab Emirates : , : Bentham Science Publishers, , [2016]; ©2016
• ISBN: 1-68108-295-0
• Descrizione fisica: 1 online resource (385 pages)
• Collana: Frontiers in Clinical Drug Research - CNS and Neurological Disorders
• Disciplina: 616.9948
• Soggetti: Central nervous system
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Includes index.
• Nota di contenuto: Intro -- CONTENTS -- PREFACE -- List of Contributors -- Multiple Sclerosis Drug Therapy: From the Classical Pharmaceutical Down to Cellular and Molecular Approach -- MULTIPLE SCLEROSIS -- Epidemiology, Environmental Agents and Genetics -- Pathogenesis -- Animal Models -- Different Immune System Players on the MS Stage -- T-cells -- B-cells -- Other Immune System Cells and the Innate Immune Response -- Histopathology -- Active Lesions -- Chronic Plaques -- Remyelinated Plaques -- Clinical Features and Diagnostic Criteria -- DISEASE-MODIFYING DRUGS -- Steroids -- Injectable Drugs -- Beta-Interferons -- Glatiramer Acetate -- Oral Drugs -- Teriflunomide -- Dimethyl Fumarate (DMF, BG-12) -- Fingolimod (FTY720) -- Conventional Immunosuppressants -- Cyclophosphamide -- Azathioprine -- Mitoxantrone -- Laquinimod -- Methotrexate -- Biologics (Monoclonal Antibodies) -- Natalizumab -- Alemtuzumab (Campath-1H) -- RECENT EMERGING BIOLOGICAL AND EXPERIMENTAL THERAPEUTICAL APPROACHES -- B-Cells -- Rituximab -- Ocrelizumab and Ofatumumab -- MEDI-551 -- Mast Cells -- Masitinib mesylate -- Cytokines and Chemokines -- Daclizumab -- Tabalumab (LY2127399) ; -- MOR103 -- Secukinumab -- Tolerogenic Vaccines for MS -- Stem Cells -- Haematopoietic Stem Cells (HSCs) -- Mesenchymal Stem Cells (MSCs) -- Helminths -- Vitamin D -- Remyelination Strategies in MS -- BIIB033 -- rHIgM22 -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Prospective Therapies for Alzheimer Disease: Biomarkers, Clinical Trials and Preclinical Research -- I. INTRODUCTION -- I.1. Background -- I.2. Alzheimer's Disease and the Need for New Drugs -- I.3. The Amyloid Cascade Hypothesis (ACH) -- I.4. Correlation among Aβ and other AD Hallmarks -- I.5. Genetics of AD -- I.5.1. APP -- I.5.2. PSEN1/PSEN2 -- I.5.3. APOE -- I.5.4 . APOJ/CLU.; I.5.5. The Role of Genetic Testing in Clinical Care -- II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT -- II.1. Biochemical Markers -- II.1.1. Cerebrospinal Fluid Biomarkers -- II.1.2. Blood Biomarkers -- II.2. Imaging-based Biomarkers -- II.2.1. Structural Magnetic Resonance Imaging -- II.2.2. Diffusion Tensor Imaging -- II.2.3. Functional Magnetic Resonance Imaging -- II.2.4. Proton Magnetic Resonance Spectroscopy -- II.2.5. Fluorodeoxyglucose-Positron Emission Tomography -- II.2.6. Amyloid-Positron Emission Tomography -- II.3. The Continuum of AD: Diagnosis and Prognosis -- II.4. Regulatory Framework -- III. PROSPECTIVE THERAPIES -- III.1. Non-immunologic Therapies -- III.1.1. Clinical Trials -- III.1.2. Preclinical Studies -- III.2. Immunotherapy -- III.2.1. Active Immunotherapy -- III.2.2. Passive Immunotherapy -- CONCLUSION AND FUTURE PERSPECTIVES -- CONFLICT OF INTEREST -- FUNDING -- ACKNOWLEDGMENTS -- REFERENCES -- At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportunities for Alzheimer's Disease? -- INTRODUCTION -- 1. BACKGROUND ON AD -- 1.1. APP Processing -- 1.2. Genetics of AD -- 1.3. Clinical Trials &amp -- Treatment Strategies -- 2. PRECLINICAL AVENUES -- 2.1. Neuroinflammation &amp -- Tumor Necrosis Factor-α -- 2.2. Network Hyperexcitability -- 3. CROSS-TALK BETWEEN SYNAPTIC HYPEREXCITABILITY &amp -- TNF -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- FUNDING -- REFERENCES -- Treatment of Diabetic Neuropathy - Current Possibilities and Perspectives -- INTRODUCTION -- DIABETES MELLITUS -- CHRONIC COMPLICATIONS OF DIABETES MELLITUS -- DIABETIC NEUROPATHY -- ETIOPATHOGENESIS OF DIABETIC NEUROPATHY -- Advanced Glycation End Products -- Oxidative Stress -- Gene Polymorphisms Of Antioxidant Enzymes And Chronic Diabetic Complications.; Polyol Pathway -- Protein Kinase C -- Hexosamine Pathway -- Low C-peptide Concentration -- Proinflammatory Cytokines -- Neurotrophic Factors -- Angiotensin-converting Enzyme -- Kinin B1 Receptor -- TREATMENT OF DIABETIC NEUROPATHY -- Treatment of Diabetes Mellitus - Adequate Compensation -- Supportive and Additional Treatment -- Alpha-lipoic Acid -- Symptomatic Treatment -- Treatment in Experimental and Clinical Studies -- Anti-inflammatory Drugs -- Neurotrophic Factors -- Angiotensin Converting enzyme (ACE) Inhibitors -- Novel Drugs with Antioxidant Functions -- Non-pharmacological Therapy -- inhibitors of Epigenetic Modifications -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENT -- REFERENCES -- The Now and Tomorrow of Migraine Treatments -- INTRODUCTION -- PATHOPHYSIOLOGICAL OVERVIEW -- ACUTE ATTACK TREATMENT -- Currently Available Drugs -- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) -- Ergot Alkaloids and Triptans -- Combination Regimens -- Narcotic Analgesics -- Hyperbaric Oxygen Therapy -- Medication Overuse Headache -- Novel Targets for Attack ; Treatment -- CGRP -- NOS Inhibition -- TRP Channels -- Glutamate Receptors -- PACAP-38 -- Cannabinoids -- The Parenchymal Inflammatory Cascade -- PROPHYLACTIC TREATMENT -- Currently Available Drugs -- Antiepileptics -- Antidepressants -- Beta Blockers -- Calcium Channel Blockers -- Glutamate Receptor Antagonists -- Triptans -- Novel Targets for Prophylactic Treatment -- CGRP -- NOS Inhibition -- Gap Junction Blockers -- Renin-Angiotensin System -- Acid Sensing Ion Channels -- Botulinum Neurotoxin -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- The Now and Tomorrow of Ischemic Stroke Treatment -- ADVANCES IN TREATMENT OF ACUTE ISCHEMIC STROKE -- Recanalization/Reperfusion -- Neuro-Glial Protection -- Prevention of Secondary Complications.; ADVANCES IN SECONDARY PROPHYLAXIS OF ISCHEMIC STROKE -- CONCLUDING REMARKS -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX.